National Agri-Marketing Association
NAMA Website
Upcoming Events
Chapters
Agri-Marketing Conf
Best of NAMA 2020












BOEHRINGER INGELHEIM LAUNCHES NEW PPV VACCINE
Source: Boehringer Ingelheim news release

Duluth, GA - Producers now have a new way to combat reproductive disease in their breeding herd. ReproCyc ParvoFLEX provides safe, efficacious protection for healthy sows and gilts 6 months of age or older against reproductive failure caused by porcine parvovirus (PPV).

PPV is a significant swine pathogen that can cause reproductive failure in dams. It is one of the three most common reproductive pathogens, along with porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus Type 2 (PCV2), which together account for more than 70% of reproductive failures linked to an infectious agent. PPV infection in pregnant sows can cause reproductive failure including fetal death and resorption, presentation of mummified fetuses at farrowing, and irregular return to estrus.

Until now, new technologies have not been applied to vaccines for this important swine disease. REPROCYC PARVOFLEX uses an adjuvanted baculovirus vector platform to produce a safe, highly immunogenic and non-virucidal vaccine. In addition, REPROCYC PARVOFLEX utilizes the recent PPV strain 27a, which research has shown to be effective in establishing a broad spectrum of protection when incorporated into vaccines. And thanks to the proprietary ImpranFLEX adjuvant, an aqueous-based (non-oil) polymer adjuvant that improves the immune response within gilts and sows, the vaccine delivers faster, long-lasting disease protection.

"PPV is no stranger to producers, but it's not always top-of-mind for them," said Dr. John Waddell, Director, Key Account Veterinarians, Swine at Boehringer Ingelheim. "When breeding herds are infected, it can cost producers unrealized potential, so our main goal in developing REPROCYC PARVOFLEX is to help prevent those losses with a safe, flexible tool."

The vaccine's efficacy was demonstrated in a vaccination-challenge study that compared gilts vaccinated with REPROCYC PARVOFLEX to non-vaccinated gilts. In the study, 96% of fetuses from vaccinated gilts were in normal condition compared to only 38% of fetuses from non-vaccinated gilts (the difference was statistically significant).

All of the non-vaccinated gilts (10) were PCR-positive for PPV on day 88 of the study (day 46 of gestation and seven days following challenge), while all vaccinated gilts (22) remained PCR-negative for PPV throughout the entire duration of the 127-day study. In addition, a primary outcome parameter for the study was evidence of PPV in fetuses as determined by PCR testing of fetal thoracic fluid. The mean number of affected fetuses in each litter was 1.41 among the vaccinated group, compared to 11.30 in the non-vaccinated group.

REPROCYC PARVOFLEX also supports mass-vaccination protocols in breeding herds and is safe to be administered at any stage of gestation.In a field safety study, of the 771 sows and gilts vaccinated with REPROCYC PARVOFLEX, 676 (87%) were observed as healthy and experienced no adverse events (AEs) throughout the course of the study.Few AEs were recorded overall in the study, and none of them were determined to be vaccine related.

For more information, visit www.SwineResource.com or contact your Boehringer Ingelheim representative.


Search News & Articles














Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © 2022, Henderson Communications LLC. | User Agreement